Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Sofpironium Bromide
Therapeutic Area : Dermatology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
No sweat for dermatology specialist Botanix as hyperhidrosis gel Sofdra gains FDA approval
Details : Sofdra (sofpironium) works by inhibiting M3 muscarinic receptors in eccrine glands. It is approved for the treatment of primary axillary hyperhidrosis in patients ages 9 and older.
Brand Name : Sofdra
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 20, 2024
Lead Product(s) : Sofpironium Bromide
Therapeutic Area : Dermatology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Sofpironium Bromide
Therapeutic Area : Dermatology
Study Phase : Phase III
Recipient : Fresh Tracks Therapeutics
Deal Size : $8.2 million
Deal Type : Agreement
Details : Under the agreement, Fresh Tracks provided consulting services as an independent contractor to Botanix in support of and through filing and approval of the U.S. new drug application for BBI-4000 (sofpironium bromide gel).
Brand Name : BBI-4000
Molecule Type : Small molecule
Upfront Cash : $8.2 million
July 21, 2023
Lead Product(s) : Sofpironium Bromide
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Recipient : Fresh Tracks Therapeutics
Deal Size : $8.2 million
Deal Type : Agreement
LOOKING FOR A SUPPLIER?